drugset / Trial / NCT02379585
Fasting on Newly Diagnosed Breast Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is to see how safe the use of short-term fasting is in breast cancer patients who will receive chemotherapy before undergoing surgery and to examine if the use of short-term fasting will decrease the side effects of chemotherapy and how much a tumor shrinks while receiving chemotherapy.
Timeline
- Start
- 2013-01
- Primary completion
- 2015-08
- Completion
- 2015-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cyclophosphamide | Other / unclassified | 600 mg/m2 | — |
| Comparator | Docetaxel | Small molecule | 75 mg/m2 | — |
| Comparator | Doxorubicin | Other / unclassified | 60 mg/m2 | — |
| Comparator | Paclitaxel | Small molecule | 75 mg/m2 | — |
| Comparator | Pertuzumab | Monoclonal antibody | 420 mg | — |
| Comparator | Trastuzumab | Monoclonal antibody | 6 mg/kg | — |